Nate’s Notes
Nate's Notes is a monthly investing newsletter and stock picking service dedicated to helping individual investors increase their wealth in the stock market by means of sound, long-term approach to investing. Since 1995, Nate's Notes has quietly become one of the top-performing investment newsletters in the country. This service is generally designed for long-term investors, and Nate Pile recommends a portfolio with 18-25 stocks as well as positions that are meant to be held for several years at a go. Each issue contains several pages of market commentary and updates on each of the stocks being recommended in the newsletter. Moreover, all buy limits and buy/sell orders are clearly spelled out for subscribers in multiple locations.
MORE ABOUT NATE'S NOTES
Nate's Notes was launched in 1995 with the goal of providing investment advice to the growing number of individual investors that he recognized were starting to do their own research.
Though the newsletter’s earliest recommendations were confined to the world of micro- and small-cap stocks, Nate’s Notes has evolved over time and now tends to focus on companies with market capitalizations ranging from a few hundred million dollars up to several hundred billion.
According to Hulbert, Nate’s Notes has been ranked among the “Top 5 for real returns” numerous times over the years, periodically holding the prestigious #1 position for one-, three-, five-, ten-, fifteen-, and 20-year returns at various points in time.
NEWSLETTER CONTENTS
What to buy and sell and when you should do it
How much you should consider paying for each stock
What the newsletters portfolio is buying and selling, including how many shares
Why he thinks each position is a good buy
The tickers symbol, name, and closing price of each stock
A portfolio recap showing exactly what has been either bought or sold since the last newsletter
ABOUT THE EDITOR
Since 1995, he has been sharing his ideas about the stock market and investing with individual investors around the world.
He started his investment career following biotechnology stocks while working for legendary biotech investor and analyst, Jim McCamant.